DK2459553T3 - Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme - Google Patents
Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdommeInfo
- Publication number
- DK2459553T3 DK2459553T3 DK10740196.0T DK10740196T DK2459553T3 DK 2459553 T3 DK2459553 T3 DK 2459553T3 DK 10740196 T DK10740196 T DK 10740196T DK 2459553 T3 DK2459553 T3 DK 2459553T3
- Authority
- DK
- Denmark
- Prior art keywords
- furazanobenzimidazoles
- neoplastic
- prodrug
- treatment
- autoimmune diseases
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166469 | 2009-07-27 | ||
| PCT/EP2010/060803 WO2011012577A1 (en) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2459553T3 true DK2459553T3 (da) | 2014-11-03 |
Family
ID=41226617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10740196.0T DK2459553T3 (da) | 2009-07-27 | 2010-07-26 | Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8802858B2 (https=) |
| EP (1) | EP2459553B1 (https=) |
| JP (1) | JP5576485B2 (https=) |
| KR (1) | KR101758400B1 (https=) |
| CN (1) | CN102471329B (https=) |
| AU (1) | AU2010277688B2 (https=) |
| BR (1) | BR112012001817B8 (https=) |
| CA (1) | CA2767875C (https=) |
| CY (1) | CY1115809T1 (https=) |
| DK (1) | DK2459553T3 (https=) |
| EA (1) | EA021380B1 (https=) |
| ES (1) | ES2524119T3 (https=) |
| HR (1) | HRP20141120T1 (https=) |
| IL (1) | IL217195A (https=) |
| MX (1) | MX336240B (https=) |
| NZ (1) | NZ597376A (https=) |
| PL (1) | PL2459553T3 (https=) |
| PT (1) | PT2459553E (https=) |
| RS (1) | RS53679B1 (https=) |
| SI (1) | SI2459553T1 (https=) |
| TW (1) | TWI457337B (https=) |
| UA (1) | UA106763C2 (https=) |
| WO (1) | WO2011012577A1 (https=) |
| ZA (1) | ZA201200228B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012098203A1 (en) | 2011-01-21 | 2012-07-26 | Basilea Pharmaceutica Ag | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
| CA2822491C (en) * | 2011-01-21 | 2023-02-14 | Basilea Pharmaceutica Ag | Bubr1 as a biomarker for furazanobenzimidazoles |
| JP6302674B2 (ja) * | 2011-01-21 | 2018-03-28 | バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ | フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用 |
| PT2678679T (pt) | 2011-02-24 | 2017-04-07 | Basilea Pharmaceutica Ag | Utilização de tubulina acetilada como um biomarcador da resposta farmacológica a furazanobenzimidazolos |
| EP2691533B1 (en) * | 2011-03-29 | 2017-04-05 | Basilea Pharmaceutica AG | Use of phospho-akt as a biomarker of drug response |
| US9558575B2 (en) | 2012-02-28 | 2017-01-31 | Blackberry Limited | Methods and devices for selecting objects in images |
| ITRM20130248A1 (it) * | 2013-04-24 | 2014-10-25 | Medivis S R L | Formulazioni di riboflavina per il cross-linking transepiteliale. |
| WO2015173341A1 (en) * | 2014-05-13 | 2015-11-19 | Basilea Pharmaceutica Ag | Dosage principle for anti-cancer furazanylbenzimidazoles |
| WO2017068182A1 (en) | 2015-10-22 | 2017-04-27 | Basilea Pharmaceutica Ag | Use of eb1 as a biomarker of drug response |
| JP2020517608A (ja) * | 2017-04-20 | 2020-06-18 | ピーアイ インダストリーズ リミテッドＰｉ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ | 新規フェニルアミン化合物 |
| MX2021011775A (es) * | 2017-04-26 | 2023-01-10 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
| US11633383B2 (en) * | 2017-05-16 | 2023-04-25 | Basilea Pharmaceutica International AG | Dosage principle for drugs useful for treating neoplastic diseases |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2020058405A1 (en) | 2018-09-20 | 2020-03-26 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) * | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| EP1472245A2 (en) * | 2002-02-06 | 2004-11-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
| WO2004103994A1 (en) * | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
| EP1723138B1 (en) * | 2004-02-11 | 2010-07-14 | Basilea Pharmaceutica AG | Substituted benzimidazoles and their use for inducing apoptosis |
-
2010
- 2010-07-26 UA UAA201201704A patent/UA106763C2/uk unknown
- 2010-07-26 PL PL10740196T patent/PL2459553T3/pl unknown
- 2010-07-26 CN CN201080033104.2A patent/CN102471329B/zh active Active
- 2010-07-26 RS RS20140669A patent/RS53679B1/sr unknown
- 2010-07-26 CA CA2767875A patent/CA2767875C/en active Active
- 2010-07-26 EA EA201200189A patent/EA021380B1/ru unknown
- 2010-07-26 AU AU2010277688A patent/AU2010277688B2/en not_active Ceased
- 2010-07-26 JP JP2012522131A patent/JP5576485B2/ja not_active Expired - Fee Related
- 2010-07-26 EP EP10740196.0A patent/EP2459553B1/en active Active
- 2010-07-26 SI SI201030829T patent/SI2459553T1/sl unknown
- 2010-07-26 BR BR112012001817A patent/BR112012001817B8/pt active IP Right Grant
- 2010-07-26 MX MX2012000611A patent/MX336240B/es unknown
- 2010-07-26 WO PCT/EP2010/060803 patent/WO2011012577A1/en not_active Ceased
- 2010-07-26 HR HRP20141120AT patent/HRP20141120T1/hr unknown
- 2010-07-26 PT PT107401960T patent/PT2459553E/pt unknown
- 2010-07-26 KR KR1020127005138A patent/KR101758400B1/ko not_active Expired - Fee Related
- 2010-07-26 DK DK10740196.0T patent/DK2459553T3/da active
- 2010-07-26 US US13/384,467 patent/US8802858B2/en active Active
- 2010-07-26 ES ES10740196.0T patent/ES2524119T3/es active Active
- 2010-07-26 NZ NZ597376A patent/NZ597376A/en not_active IP Right Cessation
- 2010-07-27 TW TW099124742A patent/TWI457337B/zh active
-
2011
- 2011-12-25 IL IL217195A patent/IL217195A/en active IP Right Grant
-
2012
- 2012-01-11 ZA ZA2012/00228A patent/ZA201200228B/en unknown
-
2014
- 2014-12-03 CY CY20141101010T patent/CY1115809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2459553T3 (da) | Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme | |
| LTPA2020510I1 (lt) | Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui | |
| DK2114886T3 (da) | Fremgangsmåde til fremstilling af visse substituerede sulfiliminer | |
| DK2448637T3 (da) | Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi | |
| DK2451796T3 (da) | Tofaanaloger til behandling af dermatologiske lidelser eller tilstande | |
| DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| DK2635282T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| DK2381965T3 (da) | Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom | |
| BR112012000434A2 (pt) | procedimento para a fabricação de piscinas naturais. | |
| DK2451482T3 (da) | Kombinationsterapi til behandlingen af diabetes | |
| DK3246042T3 (da) | Lægemiddelresistent immunterapi til behandling af cancer | |
| DK3466437T3 (da) | Middel til forebyggelse eller terapi af perinatale sygdomme for drøvtyggere | |
| DK2627345T3 (da) | Formuleringer til behandling af sygdomme i de øvre luftveje | |
| DK2382232T3 (da) | Fremgangsmåde til fremstilling af bivalirudin | |
| DK2588620T3 (da) | Fremgangsmåde til fremstilling af butanol eller acetone | |
| DK2838907T3 (da) | Aminosteroider til behandlingen af en ptp1b-associeret sygdom | |
| DK2321359T3 (da) | Fremgangsmåde til behandling af naturlige gummiprodukter | |
| DK2516359T3 (da) | Fremgangsmåde til fremstilling af ethylbenzen | |
| DK2462108T3 (da) | Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider | |
| DK3524260T3 (da) | Farmaceutiske sammensætninger til behandling af manglende appetit | |
| DK2701707T3 (da) | Fremgangsmåde til behandling af dyskinesi |